Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Sunshine Lake Pharma Co., Ltd. clinical trials
Also known as HEC Pharma, HEC Pharm.
The registry lists 86 studies whose lead sponsor is Sunshine Lake Pharma Co., Ltd. or one of 1 company grouped under it. 13 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2026.
Keep track of what changes. Save the Sunshine Lake Pharma Co., Ltd. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Sunshine Lake Pharma Co., Ltd..
- Sunshine Lake Pharma Co., Ltd.83 studiesSame company
Something wrong?
- Dongguan HEC Biopharmaceutical R&D Co., Ltd.3 studies →Subsidiary
Something wrong?
Focus areas
Conditions Sunshine Lake Pharma Co., Ltd. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 86. Browse all 86 →
- HEC53856 Tablets for Chemotherapy-induced Anemia in Non-myeloid MalignanciesNot yet recruitingNCT07891377Phase 2
- Study of Larotinib in Unresectable Advanced or Recurrent Esophageal CancerRecruitingNCT04415853Phase 3
- Single-ascending Dose Study of HEC-151 InjectionRecruitingNCT07376200Phase 1
- HEC-921 Injection as Monotherapy and in Combination With Antineoplastic Therapies in Patients With Advanced Malignant Solid TumorsRecruitingNCT07824934Phase 1
- A Safety, Tolerability, Pharmacokinetics/Pharmacodynamics Study of HEC169584 Capsules in Healthy SubjectsRecruitingNCT07099118Phase 1
- The Efficacy And Safety Of Mitizodone Phosphate Tablets In The Treatment of Patient With Major Depressive DisorderRecruitingNCT04984512Phase 2/3
- A Phase I Clinical Trial to Evaluate HECN30227 Injection in Healthy Subjects and Subjects With Chronic Hepatitis BRecruitingNCT07771140Phase 1
- A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AMLRecruitingNCT05133882Phase 1/2
- HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AMLRecruitingNCT05586074Phase 3
- A Single-center, Randomized, Open-label, Parallel-design Clinical Study to Evaluate the Pharmacokinetic Effects of Itraconazole, Fluconazole or Efavirenz on a Single Dose of Clifutinib in Healthy ParticipantsNot yet recruitingNCT07341672Phase 1
- A Study to Evaluate the Safety, Tolerability, PK/PD of HEC-007 Injection in Healthy and Overweight/Obese SubjectsRecruitingNCT07102251Phase 1
- A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) PatientsRecruitingNCT05139719Phase 2
- Confirmatory Clinical Study of HEC585 Tablets in Patients With IPFRecruitingNCT07082842Phase 3
- HEC169096 in Participants With Advanced Solid TumorsTerminatedNCT05451602Phase 1/2
- Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic FunctionWithdrawnNCT05048368Phase 1
- Study To Investigate The Potential DDI Between HEC585 And Pirfenidone/Nintedanib In Healthy SubjectsCompletedNCT07588646Phase 1
- Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping MutationsWithdrawnNCT04992858Phase 2
- A Study to Evaluate the Tolerability, Safety, Pharmacokinetics of HEC89736 in Patients With Relapsed or Refractory B-cell Hematologic MalignanciesTerminatedNCT04865458Phase 1
- Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M NegativeCompletedNCT03758287Phase 1/2
- A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Pyroglutamate Rongliflozin Capsules in Subjects With Mild and Moderate Liver DamageCompletedNCT05427682Phase 1
- The Study of a Selective 5-ht6 Receptor Antagonist, HEC30654AcOH,in Healthy SubjectsCompletedNCT03655873Phase 1
- the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC83518 TabletsCompletedNCT04667429Phase 1
- A Study of Insulin Degludec/Insulin Aspart Biosimilar (22011) Compared With Insulin Degludec/Insulin Aspart(Ryzodeg) in Participants With Type 2 Diabetes in ChinaCompletedNCT05802862Phase 3
- A Clinical Trial of HEC93077 in Chinese Healthy Subjects and HUA Patients With Single or Multiple DosingCompletedNCT05127772Phase 1
- The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC83518 Tablets in Chinses Healthy SubjectsCompletedNCT04596007Phase 1
- A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Rongliflozin in Type 2 Diabetic Subjects With Renal ImpairmentCompletedNCT05374343Phase 1
- Phase ll Study of HEC585 in Patients With IPFActive, not recruitingNCT05060822Phase 2
- Clinical Study on the Mass Balance of ClifutinibCompletedNCT07211165Phase 1
- A Study to Evaluate Drug-Drug Interaction of Larotinib With Itraconazole and Rifampin in Healthy Adult ParticipantsCompletedNCT05057949Phase 1
- Study of HEC53856 in Patients With Subjects With End-Stage Renal Disease Receiving Dialysis.CompletedNCT04925674Phase 1
- HEC53856 Phase Ib Study in Patients With Non-dialysis Renal AnemiaCompletedNCT04925661Phase 1
- Antaitavir Hasophate Capsules Combined With Yiqibuvir Tablets in Treatment Adult Patients With Chronic Hepatitis CCompletedNCT05395416Phase 2/3
- Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes MellitusCompletedNCT06148649Phase 2
Sponsor listed in the registry: Dongguan HEC Biopharmaceutical R&D Co., Ltd.
- A Clinical Trial to Evaluate Clifutinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia(AML)CompletedNCT04827069Phase 1
- Evaluation HEC121120 Tolerance in Healthy Subjects and Patients With Chronic Hepatitis B, Pharmacokinetics Characteristics and Antiviral Activity of Ⅰ Phase of StudyTerminatedNCT04536532Phase 1/2
- Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV InfectionCompletedNCT04147208Phase 2
- ADME Study of [14C] Yiqibuvir in Healthy Male SubjectsCompletedNCT05998304Phase 1
- A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of HEC96719 in Subjects With Non-Cirrhotic Non-Alcoholic SteatohepatitisCompletedNCT05397379Phase 2
- A Phase 1 Study of HEC88473 Injection in Healthy Subjects, Obese Subjects and T2DM SubjectsCompletedNCT05943886Phase 1
Sponsor listed in the registry: Dongguan HEC Biopharmaceutical R&D Co., Ltd.
- Study on the Body Mass Balance and Biotransformation of [14C]-HEC585CompletedNCT05468346Phase 1
- HEC53856 Phase 1 Study - Single and Multiple Oral Dosing in Healthy VolunteersCompletedNCT03886688Phase 1
- Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC122505MsOH Tablets in Healthy Adult SubjectsCompletedNCT04625361Phase 1
- Evaluation Freethiadine Tolerance in Healthy Subjects and Patients With Chronic Hepatitis B, Pharmacokinetics Characteristics and Antiviral Activity of Ⅰ Phase of StudyCompletedNCT05391360Phase 1
- Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC73077 in Healthy SubjectsCompletedNCT05492630Phase 1
- Single Dose and Multiple Dose Safety, Tolerability, PK，and Food Effect Study，and Interaction With Oseltamivir Study of HEC116094 in Healthy Adult SubjectsCompletedNCT04982913Phase 1
- ADME Study of [14C]- Rongliflozin in Healthy Male SubjectsCompletedNCT05109078Phase 1
- Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene AmplificationCompletedNCT03888092Phase 1/2
- ADME Study of [14C]- Larotinib in Healthy Male SubjectsCompletedNCT05059743Phase 1
- Clifutinib Food Effect Study in Healthy SubjectsCompletedNCT05454098Phase 1
- Effects of Rifampicin and Probenecid On The Pharmacokinetic Profile Of Rongliflozin In Healthy SubjectsCompletedNCT05497674Phase 1